MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation

Journal of Surgical Oncology

Volumn 96, Issue 1, 2007, Pages 62-68

  Wu, Liming ^a   Xu, Xiaobo ^a   Shen, Juwei ^a   Xie, Haiyang ^a   Yu, Songfeng ^a   Liang, Tingbo ^a   Wang, Weilin ^a   Shen, Yan ^a   Zhang, Min ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Molecular marker; Multidrug resistance 1 gene; Multivariate analysis; Single nucleotide polymorphism

Indexed keywords

GENOMIC DNA; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; CANCER RECURRENCE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENES, MDR; GENOTYPE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK;

EID: 34250326888     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20774     Document Type: Article

References (34)

1. Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-285.
2. Kew MC: Epidemiology of hepatocellular carcinoma. Toxicology 2002;181-182:35-38.
3. Lo CM, Fan ST: Liver transplantation for hepatocellular carcinoma. Br J Surg 2004;91:131-133.
4. Tan KC: Livet transplantation for hepatocellular carcinoma: How far can we push the envelope? Singapore Med J 2003;44:309-311.
5. Molmenti EP, Klintmalm GB: Cancer and liver transplantation. Transplant Rev 2000;14:183-198.
6. Marsh JW, Finkelstein SD, Demetris AJ, et al.: Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transplant 2003;9:664-671.
7. Kirimlioglu H, Dvorchick I, Ruppert K, et al.: Hepatocelluar carcinoma in native livers from patients treated with orthotopic liver transplantation: Biologic and trerapeutic implications. Hepatology 2001;34:502-510.
8. Fromm MF: Genetically determined differences in P-glycoprotein function: Implications for disease risk. Toxicology 2002;181-182:299-303.
9. Teeter LD, Estes M, Chan JY, et al.: Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog 1993;8:67-73.
10. Weinstein RS, Jakate SM, Dominguez JM, et al.: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720-2726.
11. Fujii H, Tanigawa N, Muraoka R, et al.: Clinical significance of multidrug resistance and P-glycoprotein expression in patients with gastric carcinoma. J Surg Oncol 1995;58:63-69.
12. Soini Y, Virkajarvi N, Raunio H, et al.: Expression of P-glycoprotein in hepatocellular carcinoma: A potential marker of prognosis. J Clin Pathol 1996;49:470-473.
13. Kato A, Miyazaki M, Ambiru S, et al.: Multidrug resistance gene (MDR1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001;78:110-115.
14. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al.: P-glycoprotein: From genomics to mechanism. Oncogene 2003;22:7468-7485.
15. Sakaeda T: MDR1 Genotype-related Pharmacokinetics:Fact or Fiction? Drug Metab Pharmacokinet 2005;20:391-414.
16. Tang K, Ngoi SM, Gwee C, et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12:437-450.
17. Wei-lin W, Jing J, Shu-sen Z, et al.: Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transplant 2006;12:775-780.
18. Smyth MJ, Krasovskis E, Sutton VR, et al.: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci 1998;95:7024-7029.
19. Johnstone RW, Cretney E, Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075-1085.
20. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
21. Johnstone RW, Ruefli AA, Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1-6.
22. Lasagna N, Fantappie O, Solazzo M, et al.: Hepatocyte growth Factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 2006;66:2673-2682.
23. Yi SY, Hong KS, Lim HS, et al.: A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 2004;76:418-427.
24. Jamroziak K, Mlynarski W, Balcerczak. E, et al.: Functional C3435T polymorphism of MDR1 gene: An impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004;72:314-321.
25. Illmer T, Schuler US, Thiede C, et al.: ,MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955-4962.
26. Kurzawski M, Drozdzik M, Suchy J, et al.: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005;61:389-394.
27. Potocnik U, Ravnik-Glavac M, Golouh R et al.: Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: Correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J Med Genet 2002;39:340-346.
28. Humeny A, Rodel F, Rodel C, et al. MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anticancer Res 2003;23:2735-2740.
29. Stanulla M, Schaffeler E, Arens S, et al.: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol 2005;81:39-44.
30. Siegsmund M, Brinkmann U, Schaffeler E, et al.: Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13:1847-1854.
31. Tanabe M, Ieiri I, Nagata N, et al.: Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-1143.
32. Cascorbi I, Gerloff T, Johne A, et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-174.
33. Yao FY, Bass NM, Ascher NL, et al.: Liver transplantation for hepatocellular carcinoma: Lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl. 2004;10:621-630.
34. Sharma P, Balan V, Hernandez JL, et al.: Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl 2004;10:36-41.